CD4 and tuberculosis: To improve outcomes during treatment of MDR-TB and HIV co-infection, the World Health Organization (WHO) recommends concurrent treatment with second line anti-tuberculosis drugs (SLD) and antiretroviral therapy (ART), irrespective of CD4 cell counts [11].